An Active Surveillance to Monitor the Real World Safety in Indian Patients Prescribed Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis
Phase of Trial: Phase IV
Latest Information Update: 25 Aug 2018
At a glance
- Drugs Nintedanib (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 12 Feb 2018 Planned number of patients changed from 100 to 200.
- 27 Nov 2017 Planned End Date changed from 1 Dec 2018 to 31 Dec 2019.
- 27 Nov 2017 Planned primary completion date changed from 1 Dec 2018 to 31 Dec 2019.